BRCA is the human genes which are responsible for the synthesis of tumor suppression protein in the body. Tumor suppression protein is responsible for the repairing of damaged DNA in a cell body. Therefore BRCA gene treatment is important for the tumor suppression in the body. Normally BRCA gene mutation is a risk factor for the females, any mutation in the normal body for the BRCA genes leads to the breast or ovarian cancer, so the BRCA gene mutations treatment is necessary to control the cancerous cell growth in the female body. BRCA mutation can be identified by the BRCA gene test, it is a blood test which does DNA analysis and identifies the harmful changes that may be mutations in BRCA 1 or BRCA 2 genes. After the identification of mutation physician can start the BRCA mutations treatment to the patient. For the treatment of the BRAC, a new drug class is introduced called PARP barriers. In the year 2014 U.S. FDA has approved first PARP inhibitor drug (Olaparib). This drug used in the BRAC mutation treatment for the last stage treatment ovarian cancer in the female body.
Rising patent pool suffering from breast and ovarian cancer is the key factor propelling the revenue growth of BRCA mutations treatment market over the forecast period. BRCA mutations treatment preferred as the final treatment of choice of treatment of breast and ovarian cancer, hence the demand for BRCA mutations treatment will increase rapidly over the next decade. BRCA mutations treatment used to avoid the heredity transfer of breast and ovary cancer in females, this kind of scenario may boost the BRCA mutations treatment market in coming days. Growing technological advancement in the DNA technology for the cancer diagnosis expected to fuel the growth of BRCA mutations treatment market. Globally high rate of people suffering from the fallopian and peritoneal cancer, prostate gland cancer may help to propel the growth of BRCA mutations treatment market. High end diagnostic method like MRI scan and CT scan for the early diagnosis of brain tumor may restrain the BRCA mutations treatment market. Awareness of the people about the breast cancer and ovarian caner and the control measure taken by the people for avoiding it, also restrain the growth of BRCA mutations treatment market in future.
The global BRCA mutations treatment market is classified on the basis of treatment type, caner type, end user and region.
Based on treatment type, BRCA mutations treatment market is segmented into the following:
Based caner type, BRCA mutations treatment market is segmented into the following:
Based on end user, BRCA mutations treatment market is segmented into the following:
Rising prevalence of cancer in growing age is the key factor behind the significant growth of BRCA mutations treatment market throughout the globe. By treatment type PARP inhibitors are the commonly used BARC gene mutation treatment, hence this segment may show good growth in BRCA mutations treatment market. Followed by PARP inhibitors, Chemotherapy is the second choice of the treatment for BRCA gene mutation this may show slow but growing growth in BRCA mutations treatment market. Globally, the high rate of women suffering from breast cancer in the developed countries, breast cancer treatment market expected to show the positive growth for BRCA mutations treatment market in the future. Ovarian cancer is most common in developing countries, in coming days increasing demand for ovarian cancer in developing countries may show propelling growth for BRCA mutations treatment market. By end-user hospitals, may show the high revenue share for BRCA mutations treatment market, since more people are visiting the hospitals for cancer treatment.
Among the regional presence, North America is the lucrative region for BRCA mutations treatment market which is then followed by Europe. North America registers to be the leading revenue generating segment due to the rising adoption of BRCA mutations treatment in U.S. and Canada. North America and Europe cumulatively account for a substantial revenue share in BRCA mutations treatment market. However, due to high prevalence of dry eye India and China is the key factor behind the robust the growth of BRCA mutations treatment market in South Asia and East Asia region. However, Middle East and Africa are expected to account for being least lucrative market for BRCA mutations treatment due to lack of availability cancer research centers.
Some of the key players across the value chain of BRCA mutations treatment market are AstraZeneca, GlaxoSmithKline plc., AbbVie, Clovis Oncology, TESARO, Inc., Pfizer Inc., Merck KGaA. and others.
The report on BRCA mutations treatment market covers exhaustive analysis on:
Regional analysis for BRCA mutations treatment market includes
Report on BRCA mutations treatment market highlights: